A progressive drugs policy organisation long associated with legalising marijuana in the United States has issued a stark warning. Its new report highlights serious public health risks tied to today’s high-THC cannabis products. The findings have drawn attention from across the political spectrum.

The Drug Policy Alliance (DPA) has historically championed marijuana legalisation. In March 2026, it published High-THC Marijuana: Protecting Public Health in a Changing Market. The report openly acknowledges that rising THC concentrations raise “important public health questions about safety, youth access, and consumer transparency.”

The candour is striking. For years, prevention advocates warned about high-THC cannabis. Legalisation supporters often dismissed those concerns. Now the DPA is using strikingly similar language.

High-THC Cannabis Potency Has Soared Over Three Decades

The numbers tell a sobering story. According to the National Institute on Drug Abuse, average THC concentration in seized cannabis samples rose from roughly 4% in 1995 to over 16% by 2022. That is a fourfold increase in under 30 years. Cannabis concentrates, including vape products, now frequently exceed 90% THC.

This is not the cannabis of previous generations. The DPA report attributes the surge to advances in extraction technology, commercial incentives and shifting consumer demand. Products now span a wide range of forms: edibles, beverages, oils, vapes and hard concentrates such as shatter and wax.

A Growing Body of Concern Around Potent Cannabis Products

The DPA report lists several harms tied to high-THC cannabis use. These include a greater likelihood of developing Cannabis Use Disorder and links to anxiety, depression, psychosis and schizophrenia. Young people face the highest risk. Their brains and bodies are still developing, making them more vulnerable to adverse effects.

“Young people who start using high-THC marijuana are at a greater risk of adverse effects because their brains and bodies are still developing,” the report states. Adults over 65 and those with pre-existing mental health conditions also face elevated risk.

Other public health figures have long raised similar alarms. In 2019, then-US Surgeon General Dr Jerome Adams said: “The potency is much, much higher. A higher THC content equals more danger.” Dr Nora Volkow, Director of the National Institute on Drug Abuse, warned that high-THC cannabis can trigger acute psychotic episodes. Emergency department visits linked to cannabis use have risen as a result.

The Unregulated Market Problem

A major concern in the DPA report is the regulatory gap between hemp and marijuana. Since 2018, hemp-derived products including delta-8 THC have faced little federal oversight. This allowed potent cannabis products to reach consumers, including young people, with few safeguards.

In November 2025, the US Congress passed legislation redefining hemp by total THC content rather than delta-9 THC alone. From November 2026, products exceeding 0.4 milligrams of total THC per container will fall under the federal definition of marijuana. Many delta-8 products sold legally today will lose that status overnight.

The DPA identifies this fragmentation as a core problem. Without consistent testing, labelling and age restrictions across all cannabis products, consumers face unknown potency levels and potential contaminants. Regulated businesses lose out to unaccountable competitors.

What the High-THC Cannabis Report Recommends

The DPA stops short of calling for prohibition. Instead, it sets out a regulatory approach covering standardised THC labelling, purchase limits based on potency, restrictions on youth-oriented marketing and mandatory warning labels. It also calls for marijuana tax revenue to fund mental health services, substance use treatment and prevention programmes.

The organisation urges policymakers to protect medical cannabis patients. Some rely on potent cannabis products to manage chronic pain and other conditions. Appropriate exemptions should feature in any future regulatory framework, it argues.

A 2025 Gallup poll found that 68% of Americans support marijuana legalisation. Yet that broad public support has done little to prompt tighter product safety rules. The gap between popular opinion and effective regulation is where the harm is happening.

Prevention Must Come First

Prevention advocates have noted the significance of the DPA’s shift in tone. Smart Approaches to Marijuana (SAM) observed that the report’s findings align with concerns their organisation has raised for years. The commercial framework that legalisation created still stands, however.

The tension is hard to ignore. Legalisation gave a profit-driven industry the conditions to develop and market ever stronger products to adult consumers. The public health consequences are now too visible for even legalisation advocates to overlook.

High-THC cannabis is no longer a fringe concern. It sits at the centre of a serious debate about what responsible drugs policy actually looks like, and who bears the cost when commercial interests outpace health protections.

Source: dbrecoveryresources